Predicting recurrence of non-muscle invasive bladder urothelial carcinoma: predictive value of the optimal cut-off value of Ki67
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The optimal cut-off value for Ki67 in predicting non-muscle invasive bladder urothelial carcinoma (NMIBUC) recurrence is 18%. High Ki67 expression (over 18%) is an independent risk factor for higher recurrence rates, aiding in treatment and follow-up strategies.
Area Of Science
- Urology
- Oncology
- Pathology
Background
- Non-muscle invasive bladder urothelial carcinoma (NMIBUC) recurrence poses a significant clinical challenge.
- Accurate prognostic factors are crucial for guiding patient management and treatment strategies.
Purpose Of The Study
- To determine the optimal cut-off value of the immunohistochemical marker Ki67.
- To evaluate Ki67 as a prognostic factor for predicting recurrence in NMIBUC patients.
Main Methods
- Retrospective analysis of 331 NMIBUC patients.
- Receiver Operating Characteristic (ROC) curve and Youden index to identify the optimal Ki67 cut-off value.
- Univariate, multivariate regression, and Kaplan-Meier survival analyses were performed.
Main Results
- An 18% cut-off value for Ki67 was identified as optimal for predicting NMIBUC recurrence.
- High Ki67 expression (Ki67 > 18%) was significantly correlated with tumor stage, grade, P53, and CK20 expression.
- Patients with high Ki67 expression exhibited significantly lower recurrence-free survival rates at 1 and 3 years compared to those with low Ki67 expression (P<0.001).
Conclusions
- 18% is the optimal Ki67 cut-off value for predicting NMIBUC recurrence.
- Ki67 expression > 18% is an independent risk factor for high recurrence rates.
- This finding holds potential clinical value for guiding postoperative adjuvant treatment and follow-up strategies for NMIBUC.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.